Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial

Documenti analoghi

• Immunogenicity and safety of an inactivated quadrivalent influenza vaccine: a randomized, double-blind, controlled phase III clinical trial in children aged 6–35 months in China
  di: Hu, Yuemei, et al.
  Pubblicazione: (2020)
• Safety and Immunogenicity of Sabin Strain Inactivated Poliovirus Vaccine Compared With Salk Strain Inactivated Poliovirus Vaccine, in Different Sequential Schedules With Bivalent Oral Poliovirus Vaccine: Randomized Controlled Noninferiority Clinical Trials in China
  di: Hu, Yuemei, et al.
  Pubblicazione: (2019)
• Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
  di: Wu, Zhiwei, et al.
  Pubblicazione: (2021)
• Safety and immunogenicity of a novel quadrivalent subunit influenza vaccine in animal models
  di: Ye, Huayue, et al.
  Pubblicazione: (2020)
• Development of an inactivated vaccine candidate for SARS-CoV-2
  di: Gao, Qiang, et al.
  Pubblicazione: (2020)